- Home
- ALMU vs ANNX Comparison
ALMU vs ANNX Comparison
Compare ALMU & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALMU
- ANNX
- Stock Information
- Founded
- ALMU 2019
- ANNX 2011
- Country
- ALMU United States
- ANNX United States
- Employees
- ALMU 13
- ANNX N/A
- Industry
- ALMU Semiconductors
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- ALMU Technology
- ANNX Health Care
- Exchange
- ALMU Nasdaq
- ANNX Nasdaq
- Market Cap
- ALMU 247.7M
- ANNX 263.3M
- IPO Year
- ALMU N/A
- ANNX 2020
- Fundamental
- Price
- ALMU $15.59
- ANNX $2.56
- Analyst Decision
- ALMU
- ANNX Strong Buy
- Analyst Count
- ALMU 0
- ANNX 4
- Target Price
- ALMU N/A
- ANNX $12.50
- AVG Volume (30 Days)
- ALMU 508.0K
- ANNX 1.8M
- Earning Date
- ALMU 08-07-2025
- ANNX 08-11-2025
- Dividend Yield
- ALMU N/A
- ANNX N/A
- EPS Growth
- ALMU N/A
- ANNX N/A
- EPS
- ALMU N/A
- ANNX N/A
- Revenue
- ALMU $3,627,488.00
- ANNX N/A
- Revenue This Year
- ALMU N/A
- ANNX N/A
- Revenue Next Year
- ALMU N/A
- ANNX N/A
- P/E Ratio
- ALMU N/A
- ANNX N/A
- Revenue Growth
- ALMU 335.67
- ANNX N/A
- 52 Week Low
- ALMU $2.50
- ANNX $1.29
- 52 Week High
- ALMU $19.50
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- ALMU N/A
- ANNX 54.40
- Support Level
- ALMU N/A
- ANNX $1.85
- Resistance Level
- ALMU N/A
- ANNX $2.97
- Average True Range (ATR)
- ALMU 0.00
- ANNX 0.27
- MACD
- ALMU 0.00
- ANNX 0.00
- Stochastic Oscillator
- ALMU 0.00
- ANNX 60.32
About ALMU Aeluma Inc. Common Stock
Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.